Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:3823635rdf:typepubmed:Citationlld:pubmed
pubmed-article:3823635lifeskim:mentionsumls-concept:C0087111lld:lifeskim
pubmed-article:3823635lifeskim:mentionsumls-concept:C0025815lld:lifeskim
pubmed-article:3823635lifeskim:mentionsumls-concept:C1800706lld:lifeskim
pubmed-article:3823635lifeskim:mentionsumls-concept:C0034107lld:lifeskim
pubmed-article:3823635lifeskim:mentionsumls-concept:C0348016lld:lifeskim
pubmed-article:3823635lifeskim:mentionsumls-concept:C0031928lld:lifeskim
pubmed-article:3823635lifeskim:mentionsumls-concept:C0205265lld:lifeskim
pubmed-article:3823635lifeskim:mentionsumls-concept:C1555582lld:lifeskim
pubmed-article:3823635pubmed:issue4lld:pubmed
pubmed-article:3823635pubmed:dateCreated1987-4-6lld:pubmed
pubmed-article:3823635pubmed:abstractTextTen patients with fibrosing alveolitis were treated in a simple random design initially with either a high dose of methylprednisolone (5 patients) or a conventional dose of prednisolone (5 patients) followed by a maintenance dose of 30 mg prednisolone daily. The patients were followed for 6 weeks. No significant (p greater than 0.05) differences were observed between patients with high and low initial dose of glucocorticosteroids, as regards forced vital capacity, transfer factor for carbon monoxide or symptom scores after 3 and 6 weeks of treatment. After 6 weeks the dyspnoea score and the 67Ga uptake decreased, on average, by 74 and 85%, respectively, while forced vital capacity and transfer factor increased by 15 and 29%.lld:pubmed
pubmed-article:3823635pubmed:languageenglld:pubmed
pubmed-article:3823635pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:3823635pubmed:citationSubsetIMlld:pubmed
pubmed-article:3823635pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:3823635pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:3823635pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:3823635pubmed:statusMEDLINElld:pubmed
pubmed-article:3823635pubmed:issn0025-7931lld:pubmed
pubmed-article:3823635pubmed:authorpubmed-author:GulsvikAAlld:pubmed
pubmed-article:3823635pubmed:authorpubmed-author:FrølandS SSSlld:pubmed
pubmed-article:3823635pubmed:authorpubmed-author:BergmannAAlld:pubmed
pubmed-article:3823635pubmed:authorpubmed-author:RootweltKKlld:pubmed
pubmed-article:3823635pubmed:authorpubmed-author:ValeJ RJRlld:pubmed
pubmed-article:3823635pubmed:authorpubmed-author:KjelsbergFFlld:pubmed
pubmed-article:3823635pubmed:issnTypePrintlld:pubmed
pubmed-article:3823635pubmed:volume50lld:pubmed
pubmed-article:3823635pubmed:ownerNLMlld:pubmed
pubmed-article:3823635pubmed:authorsCompleteYlld:pubmed
pubmed-article:3823635pubmed:pagination252-7lld:pubmed
pubmed-article:3823635pubmed:dateRevised2009-11-11lld:pubmed
pubmed-article:3823635pubmed:meshHeadingpubmed-meshheading:3823635-...lld:pubmed
pubmed-article:3823635pubmed:meshHeadingpubmed-meshheading:3823635-...lld:pubmed
pubmed-article:3823635pubmed:meshHeadingpubmed-meshheading:3823635-...lld:pubmed
pubmed-article:3823635pubmed:meshHeadingpubmed-meshheading:3823635-...lld:pubmed
pubmed-article:3823635pubmed:meshHeadingpubmed-meshheading:3823635-...lld:pubmed
pubmed-article:3823635pubmed:meshHeadingpubmed-meshheading:3823635-...lld:pubmed
pubmed-article:3823635pubmed:meshHeadingpubmed-meshheading:3823635-...lld:pubmed
pubmed-article:3823635pubmed:meshHeadingpubmed-meshheading:3823635-...lld:pubmed
pubmed-article:3823635pubmed:meshHeadingpubmed-meshheading:3823635-...lld:pubmed
pubmed-article:3823635pubmed:meshHeadingpubmed-meshheading:3823635-...lld:pubmed
pubmed-article:3823635pubmed:meshHeadingpubmed-meshheading:3823635-...lld:pubmed
pubmed-article:3823635pubmed:meshHeadingpubmed-meshheading:3823635-...lld:pubmed
pubmed-article:3823635pubmed:meshHeadingpubmed-meshheading:3823635-...lld:pubmed
pubmed-article:3823635pubmed:meshHeadingpubmed-meshheading:3823635-...lld:pubmed
pubmed-article:3823635pubmed:meshHeadingpubmed-meshheading:3823635-...lld:pubmed
pubmed-article:3823635pubmed:meshHeadingpubmed-meshheading:3823635-...lld:pubmed
pubmed-article:3823635pubmed:year1986lld:pubmed
pubmed-article:3823635pubmed:articleTitleHigh-dose intravenous methylprednisolone pulse therapy as initial treatment in cryptogenic fibrosing alveolitis. A pilot study.lld:pubmed
pubmed-article:3823635pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:3823635pubmed:publicationTypeClinical Triallld:pubmed
pubmed-article:3823635pubmed:publicationTypeComparative Studylld:pubmed
pubmed-article:3823635pubmed:publicationTypeRandomized Controlled Triallld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:3823635lld:pubmed